Imaging genomic mapping in glioblastoma

Neurosurgery

Volumn 60, Issue SUPPL. 1, 2013, Pages 126-130

  Zinn, Pascal O ^a   Colen, Rivka R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; TEMOZOLOMIDE;

CONFERENCE PAPER; DIFFUSION WEIGHTED IMAGING; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MAPPING; GENE MUTATION; GENOME ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; GENOMICS; GLIOBLASTOMA; HUMANS;

EID: 84885755228     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.neu.0000430773.18220.3f     Document Type: Conference Paper

References (46)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236
2. CBTRUS. Central Brain Tumor Registry of the United States Web site. Available at: Http://www.cbtrus.org/. Accessed January 1, 2013
3. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198
4. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-162
5. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3-8
6. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-764; discussion 264-266
7. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996
8. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110
9. Zinn PO, Mahajan B, Sathyan P, et al. Radiogenomic mapping of edema/ cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6(10):e25451
10. Zinn PO, Sathyan P, Mahajan B, et al. A novel volume-Age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 2012;7(8):e41522
11. Burger JA, Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107(5):1761-1767
12. Heddleston JM, Hitomi M, Venere M, et al. Glioma stem cell maintenance: The role of the microenvironment. Curr Pharm Des. 2011;17(23): 2386-2401
13. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8(20):3274-3284
14. Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: Neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 2011; 8(5):482-485
15. Waddington CH. The epigenotype: 1942. Int J Epidemiol. 2012;41(1): 10-13
16. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27-36
17. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352 (10):997-1003
19. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773
20. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199
21. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60(9):2368-2371
22. von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011;21(1):74-87
23. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897): 1807-1812
24. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007
25. SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012; 103(2):269-273
26. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342-1350
27. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715
28. Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med. 2006;79(3-4):131-140
29. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol. 2010;80(5):654-665
30. Lawler S, Chiocca EA. Emerging functions of microRNAs in glioblastoma. J Neurooncol. 2009;92(3):297-306
31. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009;19(3):188-197
32. Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987; 66(6):865-874
33. Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105(13):5213-5218
34. Pope WB, Chen JH, Dong J, et al. Relationship between gene expression and enhancement in glioblastoma multiforme: Exploratory DNA microarray analysis. Radiology. 2008;249(1):268-277
35. Pavlisa G, Rados M, Pavlisa G, et al. The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema. Clin Imaging. 2009;33(2):96-101
36. Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics. 2006;26(suppl 1):S173-S189
37. Le Bihan D. Theoretical principles of perfusion imaging: Application to magnetic resonance imaging. Invest Radiol. 1992;27(suppl 2):S6-S11
38. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25(5):746-755
39. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: Clinical applications. AJR Am J Roentgenol. 1992;159(3):591-599
40. Cho YD, Choi GH, Lee SP, Kim JK. (1)H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. Magn Reson Imaging. 2003;21(6):663-672
41. Raza SM, Fuller GN, Rhee CH, et al. Identification of necrosis-Associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004;10(1 pt 1):212-221
42. Zinn PO, Sathyan P, Veo B, et al. Radiogenomic mapping of MRI FLAIR-phenotypes identifies a novel gene-microRNA regulatory axis to target glioblastoma invasion. Available at: Http://journals.lww.com/ neurosurgery/Abstract/2012/08000/188-Radiogenomic-Mapping-of-MRI-FLAIR- Phenotypes.146.aspx. Accessed June 12, 2013
43. Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107(1):197-205
44. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629
45. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116): 116ra114
46. Jain R, Poisson L, Narang J, et al. Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: A feasibility study. AJNR Am J Neuroradiol. 2012;33(7):1343-1348